Related Experiment Video

Updated: May 17, 2026

Human Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor Therapy
12:04

Human Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor Therapy

Published on: August 14, 2012

New perspectives in the treatment of neuroendocrine tumours

Emilio Bajetta1, Laura Catena, Monica Valente

  • 1Institute of Oncology – Policlinico of Monza, Monza, Italy. emilio.bajetta@policlinicodimonza.it

Anticancer Research
|October 13, 2012
PubMed

Insights

Treatment for neuroendocrine tumours (NETs) depends on tumour aggressiveness and function. Options include surgery, hormonal therapy, chemotherapy, targeted therapies, and radiopharmaceuticals, with recent advances improving NET management.

Area of Science:

  • Oncology
  • Endocrinology
  • Nuclear Medicine

Background:

  • Neuroendocrine tumours (NETs) present diverse biological characteristics influencing treatment strategies.
  • Current therapeutic approaches for NETs are tailored to tumour aggressiveness and functional status.
  • Radical surgery remains the primary curative option for resectable NETs.

Purpose of the Study:

  • To provide an overview of current and emerging treatment modalities for neuroendocrine tumours (NETs).
  • To highlight the role of targeted therapies and radiopharmaceuticals in NET management.
  • To discuss the personalized approach to NET treatment based on tumour biology.

Main Methods:

  • Review of established and novel therapeutic strategies for NETs.
  • Analysis of treatment selection based on tumour differentiation, aggressiveness, and functional status.
  • Exploration of advancements in targeted therapies and receptor-targeted radiopharmaceuticals.

Main Results:

  • Radical surgery is the sole curative treatment for NETs.
  • Hormonal therapy is indicated for well-differentiated NETs, while chemotherapy is used for aggressive variants.
  • Targeted therapies, especially for pancreatic NETs, and radiopharmaceutical radiotherapy offer expanded treatment options.

Conclusions:

  • NET treatment requires a multidisciplinary approach, considering tumour biology and patient factors.
  • Advances in targeted therapies and radiopharmaceuticals are expanding therapeutic horizons for NETs.
  • Personalized treatment strategies are crucial for optimizing outcomes in neuroendocrine tumour patients.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...